Financial Results - Consolidated (Quarter ended June 30, 2026)

  • Revenue from operations: ₹18,796.00 million (Q1 FY2026: ₹15,426.34 million)
  • Other income: ₹198.26 million (Q1 FY2026: ₹150.19 million)
  • Total income: ₹18,994.26 million (Q1 FY2026: ₹15,576.53 million)
  • Profit before tax: ₹418.77 million (Q1 FY2026: ₹527.66 million)
  • Tax expense: ₹87.10 million (Q1 FY2026: ₹104.23 million)
  • Net profit after tax: ₹331.67 million (Q1 FY2026: ₹423.43 million)
  • Total comprehensive income: ₹331.67 million (Q1 FY2026: ₹423.43 million)
  • Basic EPS: ₹2.76 (Q1 FY2026: ₹3.54)
  • Diluted EPS: ₹2.76 (Q1 FY2026: ₹3.53)

Financial Results - Standalone (Quarter ended June 30, 2026)

  • Revenue from operations: ₹2,226.43 million (Q1 FY2026: ₹1,838.81 million)
  • Other income: ₹32.66 million (Q1 FY2026: ₹26.45 million)
  • Total income: ₹2,259.09 million (Q1 FY2026: ₹1,865.26 million)
  • Profit before tax: ₹230.17 million (Q1 FY2026: ₹176.78 million)
  • Tax expense: ₹55.66 million (Q1 FY2026: ₹41.45 million)
  • Net profit after tax: ₹174.51 million (Q1 FY2026: ₹135.33 million)
  • Total comprehensive income: ₹174.51 million (Q1 FY2026: ₹135.33 million)
  • Basic EPS: ₹1.45 (Q1 FY2026: ₹1.13)
  • Diluted EPS: ₹1.45 (Q1 FY2026: ₹1.13)

Segment Performance (Consolidated)

  • Retail segment revenue: ₹18,423.92 million (87.9% of total)
  • Diagnostic services revenue: ₹370.76 million (1.97% of total)
  • Others revenue: ₹1.32 million (0.01% of total)
  • Retail segment profit: ₹315.63 million
  • Diagnostic services profit: ₹23.24 million
  • Others segment loss: ₹(0.34) million

Key Financial Metrics

  • Equity share capital: ₹240.27 million
  • Face value per share: ₹2.00
  • Consolidated assets: ₹40,431.00 million
  • Consolidated liabilities: ₹20,324.09 million

Board Approvals

1. CAPEX Plan - Food Park: Approved ₹400 million investment for setting up Food Park including Cold Press Oil Extraction Unit at Hyderabad, Telangana by Optival Health Solutions Private Limited (material subsidiary). Project includes development of land, construction, machinery procurement, and packing lines.

2. CAPEX Plan - Health & Wellness Facility: Approved ₹1,150 million total investment (₹900 million capital expenditure) for Concierge Health & Wellness Services Facility at Hyderabad. Facility will provide preventive healthcare, diagnostics, specialist consultations through subscription-based membership model.

3. Management Appointment: Based on Nomination and Remuneration Committee recommendation, appointed Mr. Shrenik Soni (Membership No.: F12400) as Company Secretary and Compliance Officer (Key Managerial Personnel) effective July 21, 2026.

Auditor Qualifications

B S R and Co issued limited review report with following qualifications:

  • 2 subsidiaries with ₹1,923.18 million revenue and ₹10.72 million profit were reviewed by other auditors
  • 9 subsidiaries with ₹770.75 million revenue and ₹9.74 million profit were not reviewed as considered immaterial to Group
  • Figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and previously published quarterly figures

Subsidiary Information

Consolidated results include 13 subsidiaries: Nova Sud Pharmaceuticals, Wynclark Pharmaceuticals, Kalyani Meditimes, Clearancekart, Sai Sridhar Pharma, Venkata Krishna Enterprises, Shri Banashankari Pharma, Deccan Medisales, Sidson Pharma Distributors, MedPlus Insurance Brokers, MedPlus Foundation.

Meeting Details

Board meeting commenced at 2:00 PM and concluded at 4:30 PM on July 21, 2026.

Additional Information

  • New Labour Codes effective November 21, 2025 increased defined benefit obligation by ₹34.26 million and defined benefit contribution by ₹31.06 million during FY2026
  • MedPlus Foundation (wholly owned subsidiary) incorporated on May 06, 2026 and consolidated from date of incorporation
  • Documents available on company website (www.medplusindia.com) and stock exchange websites